<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03940768</url>
  </required_header>
  <id_info>
    <org_study_id>MUGdansk1</org_study_id>
    <nct_id>NCT03940768</nct_id>
  </id_info>
  <brief_title>The Use of Lactobacillus Plantarum 299v in Treatment of Cancer Patients Who Received Home Enteral Nutrition</brief_title>
  <official_title>The Use of Lactobacillus Plantarum 299v in Treatment of Cancer Patients Who Received Home Enteral Nutrition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Gdansk</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Gdansk</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the impact of Lactobacillus plantarum 299v on nutritional
      status, tolerance of enteral diet and the quality of life. Administration of this probiotic
      may potentially improve nutritional status and tolerance of enteral diet. It also may provide
      positive effect on quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study group consists of patients with cancer who are qualified for home enteral nutrition in
      Nutritional Counselling Center Copernicus in Gdansk. The control group will receive home
      enteral nutrition and placebo. The experimental group will receive home enteral nutrition and
      Lactobacillus plantarum 299v. The study is prospective and double-blind. The parameters for
      evaluation of nutritional status are: BMI, body mass analysis, level of total protein and
      albumin in blood serum, total lymphocyte count, NRS 2002 method. Assessment of the quality of
      life and tolerance of enteral diet will be done by questionaires.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 10, 2019</start_date>
  <completion_date type="Actual">March 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of fat mass</measure>
    <time_frame>at baseline and after 4th week</time_frame>
    <description>fat mass in percent (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of muscle mass</measure>
    <time_frame>at baseline and after 4th week</time_frame>
    <description>muscle mass in kilograms (kg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of total body water</measure>
    <time_frame>at baseline and after 4th week</time_frame>
    <description>total body water in percent (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of body mass index</measure>
    <time_frame>at baseline and after 4th week</time_frame>
    <description>body mass index in kg/m^2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of the albumin concentration</measure>
    <time_frame>at baseline and after 4th week</time_frame>
    <description>albumin concentration g/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of total protein concentration</measure>
    <time_frame>at baseline and after 4th week</time_frame>
    <description>total protein concentration g/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of total lymphocyte count</measure>
    <time_frame>at baseline and after 4th week</time_frame>
    <description>number of total lymphocyte count/mm^3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of enteral nutrition tolerance</measure>
    <time_frame>it will be filled every day by patients per 4 weeks treatment period</time_frame>
    <description>The enteral nutrition tolerance will be assessed with authors own questionnaire referring to number of stools, frequency of vomiting and flatulence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of patients' quality of life ( BREF - WHOQOL - Bref The World Health Organization Quality of Life)</measure>
    <time_frame>at baseline and after 4th week</time_frame>
    <description>Questionare containing questions divided in 4 domains (regarding environment, psychological, somatic, social factors). Each question gets points in scale 1-5, where 1 being the worst score. Within each domain poins are summed up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Lactobacillus plantarum 299v receivers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sanprobi IBS (Lactobacillus plantarum 299v) 2 capsules per day for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo receivers</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sanprobi IBS placebo 2 capsules per day for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus plantarum 299v</intervention_name>
    <description>Administration of Lactobacillus plantarum 299v in cancer patients who receive home enteral nutrition.</description>
    <arm_group_label>Lactobacillus plantarum 299v receivers</arm_group_label>
    <arm_group_label>Placebo receivers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administration of placebo in cancer patients who receive home enteral nutrition.</description>
    <arm_group_label>Lactobacillus plantarum 299v receivers</arm_group_label>
    <arm_group_label>Placebo receivers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age ≥18 yr.,

          -  the presence of cancer, artificial access to the alimentary tract (naso-gastric tube,
             gastrostomy, percutaneous endoscopic gastrostomy, jejunostomy, microjejunostomy),

          -  qualification for home enteral nutrition,

          -  written consent to take part in the study

        Exclusion Criteria:

          -  age &lt;18 yr.,

          -  patients requiring home parenteral nutrition,

          -  patients who are not being able to attend the visit in the study centre.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nutritional Counselling Centre Copernicus in Gdansk</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 31, 2019</study_first_submitted>
  <study_first_submitted_qc>May 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Gdansk</investigator_affiliation>
    <investigator_full_name>Karolina Kaźmierczak-Siedlecka</investigator_full_name>
    <investigator_title>Karolina Kaźmierczak-Siedlecka (nutritionist, PhD student - Department of Surgical Oncology)</investigator_title>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>home enteral nutrition</keyword>
  <keyword>probiotic</keyword>
  <keyword>Lactobacillus plantarum 299v</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

